Dopamine agonist utilization prior to the initiation of device aided therapy: data from 150 patients with advanced Parkinson’s disease treated with Levodopa Carbidopa Intestinal Gel
Objective: Objective: To evaluate the usage of dopamine agonists (DA) as part of the last conventional dopaminergic treatment in a large cohort of consecutive patients…Aromatic L-amino acid decarboxylase deficiency: A rare disease case report and literature review
Objective: We review the presentation of a 3-month-old patient who came to our institution with symptoms of dystonia, oculogyric crises, hypotonia, developmental delay, and dysphagia,…Experience with apomorphine infusion cartridge in France – evaluation of patient and healthcare team benefits
Objective: To evaluate ‘real-world’ benefits for patients with Parkinson’s disease (PD) and impact on healthcare team practice of the introduction of apomorphine infusion (APO) cartridge…USE OF NIGHT TIME CONTINUOUS SUBCUTANEOUS INFUSION OF APOMORPHINE (NCSAI) IN ADVANCED PARKINSON’S DISEASE: A SERIES OF 37 CASES.
Objective: The aim of this study is to evaluate the feasibility, efficacy and safety of NCSAI administration in patients with Advanced Parkinson disease (APD). Background:…Case report: Parkinsonim with dyskinesia secondary to amyloid angiopathy
Objective: To report a case of parkinsonism secondary to amyloid angiopathy and discuss the pathophysiology and treatment of this entity. Background: Cerebral amyloid angiopathy is…Availability and accessibility of medicines for patients with Parkinson’s disease in Kyrgyzstan
Objective: The aim of the study was to assess the availability and accessibility of medicines for patients with Parkinson’s disease (PD) in Kyrgyzstan. Background: After…Distinct oscillatory fingerprints in dyskinesias mediated by D1 versus D2 receptors
Objective: To characterize the patterns of cortico-basal ganglia oscillations induced by D1 or D2 receptor agonists in a rat model of L-DOPA-induced dyskinesia. Background: In…Using a Dopamine Genetic Risk Score to Predict Impulse Control Behaviours for Parkinson’s Disease Patients
Objective: The current study aimed to utilise a dopamine genetic risk score and objective laboratory-based behavioural measures of impulse control to identify Parkinson’s patients most…Motor and non-motor effects of mevidalen in Lewy Body Dementia as measured by the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)
Objective: To assess the motor and non-motor effects of mevidalen in patients with Lewy Body Dementia (LBD) as measured by the MDS-UPDRS. Background: Mevidalen is…Limitations of conventional dopaminergic medication in advanced Parkinson’s disease: results from 127 patients treated with Levodopa Carbidopa Intestinal Gel
Objective: To evaluate the characteristics of the last conventional dopaminergic treatments in a large cohort of patients with advanced Parkinson’s Disease (APD) treated with Levodopa…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 13
- Next Page »